People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Atsena Therapeutics, Inc. | — | Biotechnology | Series C | $146.0M | $606.4M | 2023 |
Jennifer Wellman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jennifer Wellman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Healy | 1 | 8 |
| Norbert Riedel | 1 | 4 |
| Michael Dial | 1 | 4 |
| Jacqueline Grant | 1 | 3 |
| Benjamin Yerxa | 1 | 2 |
| Patrick Ritschel | 1 | 2 |
| Sanford Boye | 1 | 1 |
| Christina Isacson | 1 | 1 |
| Chris Carpenter | 1 | 1 |
| Joe Zakrzewski | 1 | 1 |
| Shannon Boye | 1 | 1 |
| Elizabeth Leiderman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.